SCLC Clinical Trial Timeline: A 25-Year Dual-Track Map

Tue, 21 Apr 2026 00:00:00 +0000

SCLC Clinical Trial Timeline: In-Depth Research Report

Coverage: 30 landmark trials cited by NCCN Small Cell Lung Cancer V1.2026 (28 published with full PMID traceability + 2 design/protocol papers with primary results pending) + two stages (LS-SCLC limited-stage / ES-SCLC extensive-stage) + five paradigms (concurrent chemoradiation / 1L chemoimmunotherapy / PCI / 2L and later lines / maintenance exploration)

Curated by Dual Brain Lab (csilab.net)

1. One-Sentence Definition

This report maps the evolution logic and current decision landscape of landmark clinical trials for systemic treatment of small cell lung cancer (SCLC) cited by NCCN Small Cell Lung Cancer V1.2026 over the past 27 years (1999-2026), providing frontline clinicians in 2026 a traceable panoramic map for “who, what, and why” decisions.

Iron rule: every data point in every trial is traceable to PubMed (PMID) or ClinicalTrials.gov (NCT id) — each [PMID xxxxxxxx] in the text can be directly opened for PubMed source verification.

2. Longitudinal: Evolution Timeline of Five Treatment Paradigms

SCLC systemic treatment has undergone five paradigm shifts over 27 years: LS-SCLC (limited-stage) concurrent chemoradiation established by Turrisi 1999 hyperfractionated acceleration → ES-SCLC (extensive-stage) etoposide + platinum (EP) backbone and 2L topotecan 20-year plateau → thoracic radiotherapy + PCI (prophylactic cranial irradiation) filled the brain-protection gap during 2007-2015 → 2018 IMpower133 and 2019 CASPIAN broke the 20-year OS (overall survival) ceiling using PD-(L)1 inhibitor class effect → 2024 ADRIATIC upgraded LS-SCLC to cCRT (concurrent chemoradiation) + durvalumab consolidation as the new standard, while in the same year DeLLphi-301 opened SCLC’s first truly non-chemotherapy new mechanism in half a century using tarlatamab (DLL3 × CD3 BiTE, bispecific T-cell engager).

Each shift has been smaller in magnitude than in NSCLC — reflecting SCLC’s unique biology: no unified driver mutation + neuroendocrine differentiation + MYC / ASCL1 / NEUROD1 / POU2F3 / YAP1 molecular subtype heterogeneity + rapid chemoresistance + low tumor mutation burden (TMB) → the NSCLC “EGFR/ALK/KRAS ten-gene + IO backbone” model does not apply to SCLC. SCLC’s paradigm evolution follows a three-stage arc: “20-year chemotherapy plateau + IO marginal victory + DLL3 BiTE breakthrough.”

2.1 LS-SCLC Concurrent Chemoradiation Foundations (1999-2024): BID acceleration → QD non-inferiority → SIB dose escalation

Story: in 1999 TURRISI INT-0096 pushed LS-SCLC radiotherapy from QD (once daily) 5 weeks to BID (twice daily) 3 weeks 45 Gy hyperfractionated acceleration, raising 2-year OS from 41% to 47%. But BID had poor clinical feasibility (twice-daily outpatient radiotherapy + esophagitis), so for 18 years Europe and North America wanted to return to QD but lacked evidence, until CONVERT proved 66 Gy QD non-inferior, validating the “more convenient dose” approach, and CALGB-30610 used 70 Gy QD to confirm numerical closeness. In 2024 Yu et al used SIB (simultaneous integrated boost) 54 Gy BID to push mOS to 60.7 months — the first time a Chinese cohort raised the radiotherapy dose further.

INT-0096 (TURRISI 1999) [PMID 9920950] (Turrisi 1999 NEJM): LS-SCLC 45 Gy BID 3 weeks vs 45 Gy QD 5 weeks + cisplatin/etoposide. mOS 23 vs 19 months (p=0.04), 2-year OS 47% vs 41%, 5-year OS 26% vs 16%. Grade 3 esophagitis 32% vs 16%. Established “LS-SCLC cCRT + BID 45 Gy” as North American SoC (standard of care) for 25 years.
CONVERT [PMID 28642008] (Faivre-Finn 2017 Lancet Oncol): LS-SCLC 66 Gy QD 6.5 weeks vs 45 Gy BID 3 weeks + cisplatin/etoposide. mOS 30 months (BID) vs 25 months (QD), HR 1.18 (95% CI 0.95-1.45, p=0.14) — non-inferiority achieved, toxicity profiles similar. Europe and North America finally had evidence that “QD is non-inferior to BID,” and clinical practice shifted back to QD.
CALGB 30610 / RTOG 0538 [PMID 36623230] (Bogart 2023 JCO): LS-SCLC 70 Gy QD vs 45 Gy BID + platinum-etoposide. mOS 30.1 vs 28.5 months, HR 0.94 (95% CI 0.76-1.17). 70 Gy QD confirmatory in North America, aligned with CONVERT — high-dose QD = standard-dose BID.
YU-2024-HYPERFRAC [PMID 39146944] (Yu 2024 Lancet Respir Med): LS-SCLC VMAT 54 Gy SIB BID 30 fractions vs 45 Gy BID 30 fractions. mOS 60.7 vs 39.5 months, HR 0.55 (95% CI 0.37-0.72, p=0.003) — adding 9 Gy gained 21 months of OS. Grade 3-4 esophagitis 11% vs 4%. Bold Chinese single-center design, awaiting Western confirmatory trials.
ADRIATIC [PMID 39268857] (Cheng 2024 NEJM): LS-SCLC post-cCRT non-progressors, durvalumab 1500 mg q4w consolidation for up to 24 months vs placebo. mOS 55.9 vs 33.4 months, HR 0.73 (98.321% CI 0.54-0.98, p=0.01), mPFS 16.6 vs 9.2 months. First time in 30 years that post-cCRT OS was significantly extended in LS-SCLC — the SCLC version of PACIFIC’s playbook for stage III NSCLC moving from cCRT observation to durvalumab consolidation.
NRG LU005 [PMID 41529214] (Higgins 2026 JCO): LS-SCLC cCRT (66 Gy QD or 45 Gy BID) + atezolizumab concurrent + adjuvant 17 cycles vs cCRT alone. mOS 31.1 vs 36.1 months, HR 1.03 (95% CI 0.80-1.32) negative. “Concurrent IO + cCRT” failed in LS-SCLC — “sequential durvalumab consolidation” (ADRIATIC) is the correct path.

Takeaway: in 2026, LS-SCLC SoC = cCRT (either BID 45 Gy or QD 66-70 Gy) → durvalumab consolidation up to 24 months (ADRIATIC). The “concurrent IO + cCRT” path (NRG LU005) has been refuted. Yu 2024’s 54 Gy SIB dose escalation is a Chinese single-center exploratory signal awaiting larger confirmatory trials.

2.2 ES-SCLC 1L Chemotherapy Plateau (1999-2019): EP backbone 20 years + topotecan vs CAV anchoring 2L

Story: before the IO era, 1L standard for ES-SCLC was EP (etoposide + platinum) 4-6 cycles with an mOS ceiling of 9-10 months. All attempts to add a third drug (paclitaxel / lobaplatin substitution) failed and only doubled toxicity. 2L topotecan, after a 1999 phase III vs CAV (cyclophosphamide + doxorubicin + vincristine) proved single-agent non-inferiority + better quality of life, sat firmly as the 2L standard until tarlatamab arrived in 2024.

TOPOTECAN-ORIGINAL-PHASE2 [PMID 10080612] (von Pawel 1999 JCO): relapsed SCLC topotecan 1.5 mg/m² d1-5 q21d vs CAV. ORR 24.3% vs 18.3% (p=0.285), mTTP (time to progression) 13.3 vs 12.3 weeks (p=0.552), mOS numerically close. Single-agent topotecan non-inferior to three-drug CAV + better symptom improvement — established topotecan as SCLC 2L standard for 20+ years.
NIELL-2002-INTERGROUP [PMID 15923572] (Niell 2005 JCO): ES-SCLC 1L paclitaxel + EP + G-CSF vs EP × 6 cycles. mOS 10.6 vs 9.9 months, p=0.169 negative, G3-4 toxicity increased. “Add a taxane to EP” approach refuted — EP is the ES-SCLC 1L chemotherapy ceiling.
OBRIEN-TOPOTECAN-2006 [PMID 17135646] (O’Brien 2006 JCO): relapsed SCLC oral topotecan 2.3 mg/m² d1-5 q21d + BSC (best supportive care) vs BSC alone. mOS 25.9 vs 13.9 weeks (log-rank p=0.0104), ORR 7% PR + 44% DCR. Oral topotecan vs BSC established that “even when no new drug is available, 2L topotecan beats BSC” — the minimum-care baseline for SCLC 2L.
EL-PHASE3-CHINA [PMID 30988825] (Cheng 2019 Oncol Lett): ES-SCLC 1L lobaplatin + etoposide (EL) vs cisplatin + etoposide (EP). mPFS 5.1 vs 5.3 months (p=0.786), mOS 10.6 vs 9.7 months (p=0.701). Chinese non-inferiority demonstrated lobaplatin vs cisplatin equivalence in ES-SCLC 1L, providing a platinum alternative for patients intolerant to nephrotoxicity / vomiting — the last “chemotherapy optimization” before the IO era.

Takeaway: across these 20 years (1999-2019), ES-SCLC 1L ceiling held steady at mOS 9-10 months, 2L topotecan single-agent at ~25 weeks — two “plateau” numbers defined what IO had to break. All attempts to add a third chemo drug / substitute the platinum failed.

2.3 ES-SCLC Thoracic RT + PCI Brain Protection (2007-2021): add RT + PCI → dose + fraction optimization

Story: before 2007, ES-SCLC post-chemo responders went straight to observation. Slotman 2007 proved PCI 25 Gy after chemo response substantially reduced brain metastases and extended OS; CREST 2014 proved thoracic RT 30 Gy/10 fx also delivered 2-year OS benefit. From 2009-2021 three trials (PCI99-01 dose optimization + RTOG-0212 hippocampal avoidance) refined PCI to “low dose + cognitive protection.”

SLOTMAN-PCI-2007 [PMID 17699816] (Slotman 2007 NEJM): ES-SCLC post-chemo response PCI 25 Gy vs observation. 1-year symptomatic brain metastasis risk 14.6% vs 40.4% (HR 0.27, 95% CI 0.16-0.44, p<0.001), 1-year OS 27.1% vs 13.3% (HR 0.68, 95% CI 0.52-0.88, p=0.003). Pivotal evidence establishing ES-SCLC PCI as SoC, widely adopted globally after 2007.
PCI99-01 [PMID 19386548] (Le Péchoux 2009 Lancet Oncol): LS-SCLC cCRT CR (complete response) PCI 36 Gy vs 25 Gy dose comparison. 2-year brain metastases 23% vs 29% (36 Gy vs 25 Gy), HR 0.80 (95% CI 0.57-1.11) negative; 36 Gy arm had more chronic neurotoxicity. 25 Gy low dose non-inferior + less toxicity — LS-SCLC PCI standard dose locked at 25 Gy.
CREST (SLOTMAN-2015) [PMID 25230595] (Slotman 2015 Lancet): ES-SCLC post-chemo response thoracic RT 30 Gy/10 fx + PCI vs PCI alone. 1-year OS 33% vs 28% (HR 0.84, 95% CI 0.69-1.01, p=0.066 not significant), 2-year OS 13% vs 3% (p=0.004 significant). “Long-tail OS benefit” — a subset of patients indeed benefits from thoracic RT, but not significant at the 1-year landmark. NCCN retains as an optional option.
RTOG-0212-HIPPO (Belderbos 2021) [PMID 33545387] (Belderbos 2021 JTO): SCLC post-chemo PCI 25 Gy standard whole-brain vs HA-PCI (hippocampal-avoidance PCI) 25 Gy. 4-month HVLT-R total recall decline ≥5 points: 29% vs 28% (p=1.000) — HA-PCI did not show clear cognitive protection advantage in this study, inconsistent with earlier small-scale NRG CC001 data. Guideline wording retains HA-PCI as optional but evidence is not coherent.

Takeaway: 2026 PCI decisions — LS-SCLC cCRT CR then PCI 25 Gy (PCI99-01 dose-locked) remains SoC; ES-SCLC post-chemo response PCI 25 Gy based on Slotman 2007 but in the IO era some European centers substitute brain MRI surveillance (lacks head-to-head RCT); CREST thoracic RT kept as an option (strong 2-year OS signal but 1-year OS not significant); HA-PCI evidence is inconsistent (RTOG-0212 negative).

2.4 ES-SCLC 1L IO Breakthrough (2018-2025): class-effect marginal victory + Chinese PD-1 catch-up

Story: in 2018 IMpower133 used atezolizumab + chemo to push ES-SCLC’s 20-year ceiling from mOS 10 months to 12.3 months, HR 0.70 — the first positive phase III for IO in SCLC 1L. In 2019 CASPIAN reproduced the same path with durvalumab, HR 0.73. Two independent phase IIIs converging in the narrow HR 0.70-0.73 band = textbook definition of class effect. From 2022-2025, five domestic Chinese phase IIIs (ASTRUM-005 serplulimab / CAPSTONE-1 adebrelimab / RATIONALE-312 tislelizumab / EXTENTORCH toripalimab / ETER701 benmelstobart + anlotinib) propelled ES-SCLC 1L into a “Chinese PD-1/PD-L1 flourishing” era, with Chinese regimens’ mOS numerically higher than IMpower133/CASPIAN (15-19 months vs 12-13 months), though cross-trial population differences require cautious interpretation.

IMPOWER133 [PMID 30280641] (Horn 2018 NEJM): ES-SCLC treatment-naïve atezolizumab + carboplatin + etoposide vs placebo + carboplatin + etoposide. mOS 12.3 vs 10.3 months (HR 0.70, 95% CI 0.54-0.91, p=0.007), mPFS 5.2 vs 4.3 months (HR 0.77, p=0.02). First OS-positive phase III in SCLC in 20 years. FDA approved 2019-03.
IMBRELLA-A (IMpower133 5y) [PMID 39306923] (Reck 2024 Lung Cancer): IMpower133 ITT 5-year long-term follow-up extension. 3/4/5-year OS atezolizumab arm 16%/13%/12% — “long-tail survivor” confirmed, about 12% of patients alive at 5 years (historical chemo-alone 3-4%). IO benefit concentrated in a “durable responder” subgroup, not uniformly lifting the entire population.
CASPIAN [PMID 31590988] (Paz-Ares 2019 Lancet): ES-SCLC treatment-naïve durvalumab + platinum-etoposide (EP/EC) vs EP/EC. mOS 13.0 vs 10.3 months (HR 0.73, 95% CI 0.59-0.91, p=0.0047). Global regimen + durvalumab maintenance through progression (rather than stopping at 4-6 cycles). FDA approved 2020-03, HR converging with IMpower133 in the 0.70-0.73 band — establishing IO + platinum/etoposide class effect.
ASTRUM-005 [PMID 36166026] (Cheng 2022 JAMA): ES-SCLC treatment-naïve serplulimab (HLX10 PD-1) + carboplatin + etoposide vs placebo + carboplatin + etoposide. mOS 15.4 vs 10.9 months (HR 0.63, 95% CI 0.49-0.82, p<0.001), 24-month OS rate 43.1% vs 7.9%. First Chinese PD-1 to post OS HR 0.63 in ES-SCLC 1L — numerically higher than IMpower133/CASPIAN, population predominantly Asian.
CAPSTONE-1 [PMID 35576956] (Wang 2022 Lancet Oncol): ES-SCLC treatment-naïve adebrelimab (SHR-1316 PD-L1) + carboplatin + etoposide vs placebo + carboplatin + etoposide. mOS 15.3 vs 12.8 months (HR 0.72, 95% CI 0.58-0.90). Chinese PD-L1 version of IMpower133 repeat, HR close to CASPIAN.
RATIONALE-312 [PMID 38460751] (Cheng 2024 JTO): ES-SCLC treatment-naïve tislelizumab (PD-1) + etoposide + carboplatin/cisplatin vs placebo + etoposide + carboplatin/cisplatin. mOS 15.5 vs 13.5 months (HR 0.75, 95% CI 0.61-0.93, one-sided p=0.0040). The third Chinese IO confirming class effect.
EXTENTORCH [PMID 39541202] (Cheng 2025 JAMA Oncol): ES-SCLC treatment-naïve toripalimab (PD-1) + EP vs placebo + EP. mOS 14.6 vs 13.3 months (HR 0.80, 95% CI 0.65-0.98, p=0.03), PFS HR 0.67. The fourth Chinese IO added to EP.
ETER701 [PMID 38992123] (Cheng 2024 Nat Med): ES-SCLC treatment-naïve benmelstobart (PD-L1) + anlotinib (multi-target TKI) + etoposide + carboplatin four-drug regimen vs dual placebo + etoposide + carboplatin. Four-drug arm mOS 19.3 vs 11.9 months (HR 0.61, p=0.0002); anlotinib + EC (three-drug arm) also superior to EC. Highest mOS record in ES-SCLC 1L history; G3+ TRAE 93.1% approaching universal. “Adding anti-angiogenic TKI to IO + chemo” is the new intensification direction for ES-SCLC 1L, but at a high toxicity cost.

Takeaway: in 2026, ES-SCLC 1L SoC = IO + platinum/etoposide × 4-6 cycles → IO maintenance (atezolizumab / durvalumab / serplulimab / adebrelimab / tislelizumab / toripalimab, any one; class effect HR 0.63-0.80 narrow band). ETER701 four-drug regimen mOS 19.3 months is the Chinese exploration peak but toxicity cost is high; choice depends on clinical tradeoff. The “long-tail 12% 5-year survival” is the most critical structural change in the IO era for ES-SCLC — not raising everyone’s OS by 2-3 months, but giving 12% of “durable responders” a 5-year+ survival window.

2.5 ES-SCLC 2L+ and Maintenance Exploration (2016-2026): tarlatamab DLL3 BiTE breakthrough + IO monotherapy failure + flourishing maintenance combinations

Story: IO monotherapy was initially given high hopes in SCLC 2L+; CheckMate-032 nivolumab ± ipilimumab and KEYNOTE-028/158 pembrolizumab both showed ORR 10-22% signals, but without phase III level OS evidence, FDA successively withdrew these two SCLC indications during 2018-2020 — IO monotherapy in unselected 2L populations is not practice-changing. Until 2023, when DeLLphi-301 used tarlatamab (DLL3 × CD3 BiTE) in 2L+ to achieve cORR 40%, mDoR (median duration of response) 6.9 months, and FDA accelerated approval 2024-05, marking the first time in half a century SCLC had a “non-chemotherapy new mechanism” receive regulatory approval. From 2024-2026 maintenance/combination explorations (DeLLphi-303 / DURABLE / TREASURE / MATCH) rolled out densely, exploring four combination directions: “IO + tarlatamab / IO + anti-angiogenic / IO + thoracic RT / IO + low-dose RT.” TRACES used trilaciclib to reposition myeloprotection as an SCLC chemotherapy adjunct.

CHECKMATE-032 [PMID 27269741] (Antonia 2016 Lancet Oncol): relapsed SCLC nivolumab monotherapy or nivolumab + ipilimumab various doses. ORR: nivo3 10% (10/98), nivo1+ipi3 23% (14/61), nivo3+ipi1 19% (10/54); durable response signal but small sample, no control. FDA 2018-08 accelerated approval for nivolumab SCLC 3L based on this basket data, but withdrawn 2020-12 (CheckMate-331/451 confirmatory failed).
KEYNOTE-028-158 [PMID 31870883] (Chung 2020 JTO): relapsed SCLC ≥2L pembrolizumab monotherapy pooled analysis. ORR 19.3% (95% CI 11.4-29.4), 2 CR + 14 PR, 61% of responders DoR ≥18 months. FDA 2019-06 accelerated approval for pembrolizumab SCLC 3L, withdrawn 2021-03 (KEYNOTE-604 1L confirmatory negative). IO monotherapy in unselected 2L+ SCLC showed seemingly decent ORR but no phase III OS support — what regulators ultimately required.
DELLPHI-301 [PMID 37861218] (Ahn 2023 NEJM): previously treated SCLC 2L+ tarlatamab 10 mg or 100 mg IV every 2 weeks. ORR 40% (10 mg arm, cORR 40% per BICR) vs 32% (100 mg), mPFS 4.9 vs 3.9 months, 9-month OS 68% (10 mg arm), mDoR 6.9 months. Severe CRS (cytokine release syndrome) 1%, low-grade CRS ~50% mostly at first dose, managed via step-up dosing. First non-chemotherapy non-IO new mechanism in SCLC in half a century — FDA accelerated approval 2024-05.
DELLPHI-303 [PMID 40934933] (Paulson 2025 Lancet Oncol): ES-SCLC 1L post-chemoimmunotherapy tarlatamab + atezolizumab or durvalumab maintenance. From maintenance start mOS 25.3 months (95% CI 20.3-NE), severe CRS 24% — safety signal in 1L maintenance setting is manageable. Phase III NCT06211036 ongoing, expected to push tarlatamab from 2L+ to 1L maintenance.
DURABLE [PMID 37947242] (Zhang 2023 Clin Respir J, protocol paper): ES-SCLC 1L post-chemo response durvalumab + anlotinib maintenance vs durvalumab maintenance. Only protocol published, primary efficacy results not yet PubMed-indexed (conference reports PFS 9.0 vs 5.6 months) — representative of “anti-angiogenic + IO combination maintenance” direction.
TREASURE [PMID 36153496] (Bozorgmehr 2022 BMC Cancer, protocol paper): ES-SCLC 1L post-response atezolizumab + thoracic RT (TRT) vs atezolizumab maintenance alone. Protocol design stage; trial terminated due to toxicity. CREST thoracic RT + IO maintenance verification attempt failed.
MATCH-TRIAL-SCLC [PMID 40609842] (Zhou 2026 Int J Radiat Oncol Biol Phys): ES-SCLC 1L cisplatin/carboplatin + etoposide + atezolizumab + concurrent low-dose RT (LDRT, 15 Gy/5 fx). Confirmed ORR 87.5% (95% CI 75.9-94.8), mPFS 6.9 months (95% CI 5.4-9.3) — single-arm phase II, early signal for “LDRT + IO + chemo” in ES-SCLC 1L, ORR far higher than IMpower133/CASPIAN. Awaiting phase III validation.
TRACES [PMID 38224653] (Cheng 2024 Lung Cancer): ES-SCLC chemotherapy trilaciclib (CDK4/6 inhibitor myeloprotection) pre-dosed vs placebo + etoposide + carboplatin. Cycle 1 DSN (duration of severe neutropenia) 0 vs 2 days (p=0.0003), mOS 12.0 vs 8.8 months (HR 0.69, 95% CI ). Trilaciclib already FDA-approved in the US 2021 — turning chemotherapy myelosuppression from “unavoidable side effect” into “pharmacologically preventable.”

Takeaway: in 2026, SCLC 2L+ SoC = tarlatamab (DeLLphi-301, FDA 2024-05 accelerated) is the preferred non-chemotherapy new mechanism; single-agent topotecan or lurbinectedin (FDA 2020 accelerated, not in this yaml) as non-BiTE alternatives; IO monotherapy (nivolumab / pembrolizumab) SCLC indications withdrawn, limited to tumor-agnostic MSI-H / TMB-H. The four maintenance/combination directions (tarlatamab maintenance / anti-angiogenic maintenance / thoracic RT + IO / LDRT + IO) are the most active battlegrounds for 2026-2028.

3. Horizontal: 2026 Current Decision Landscape (Six Dimensions)

Projecting longitudinal evolution onto 2026’s concrete clinical decision tree, the following are six key branchpoints and the evidence underpinning each.

3.1 LS-SCLC Initial Treatment: cCRT + durvalumab consolidation, new standard

2026 mainstream: curative-intent LS-SCLC fit patients = cCRT (cisplatin/etoposide × 4-6 cycles + thoracic RT 45 Gy BID / 3 weeks or 66-70 Gy QD / 6-7 weeks) → post-cCRT non-progressors durvalumab 1500 mg q4w consolidation up to 24 months → CR patients PCI 25 Gy or brain MRI surveillance.

Key branchpoints:

Subgroup	First choice	Alternative
fit LS-SCLC standard risk	cCRT (45 Gy BID / 66 Gy QD) → durvalumab consolidation (ADRIATIC) → PCI 25 Gy [TURRISI PMID 9920950 / CONVERT PMID 28642008 / ADRIATIC PMID 39268857 / PCI99-01 PMID 19386548]	70 Gy QD [CALGB 30610 PMID 36623230]
fit LS-SCLC Chinese center (exploratory)	54 Gy SIB BID [YU-2024 PMID 39146944] → durvalumab consolidation	Return to 45 Gy BID + ADRIATIC consolidation
IO intolerant / active autoimmunity	cCRT standard dose + observation (no durvalumab consolidation)
Elderly / PS 2 LS-SCLC	Sequential chemoradiation (SeqCRT) instead of cCRT, toxicity de-escalation
cCRT failure / progression	2L per ES-SCLC 2L+ decision

Not recommended in 2026: concurrent atezolizumab + cCRT — NRG LU005 (PMID 41529214) HR 1.03 negative + OS numerically lower (31.1 vs 36.1 months); “concurrent IO + cCRT” in LS-SCLC does not replicate the PACIFIC stage III NSCLC script.

3.2 ES-SCLC 1L: IO + platinum/etoposide class effect + Chinese PD-1 accessibility branch

2026 mainstream: ES-SCLC fit treatment-naïve = IO (PD-(L)1 inhibitor, 6-7 choices) + carboplatin or cisplatin + etoposide × 4-6 cycles → IO maintenance until progression or intolerance.

Key branchpoints:

Subgroup	First choice	Alternative
fit global / Western	atezolizumab + carboplatin + etoposide [IMpower133 PMID 30280641 + 5y PMID 39306923] or durvalumab + EP/EC [CASPIAN PMID 31590988]	EP/EC alone (IO intolerant)
fit China / Asia	serplulimab + carboplatin + etoposide [ASTRUM-005 PMID 36166026] or adebrelimab + carboplatin + etoposide [CAPSTONE-1 PMID 35576956] or tislelizumab + EP/EC [RATIONALE-312 PMID 38460751] or toripalimab + EP [EXTENTORCH PMID 39541202]	atezolizumab / durvalumab (when accessible)
fit, seeking highest OS + willing to tolerate ~93% G3+ toxicity	benmelstobart + anlotinib + EC four-drug [ETER701 PMID 38992123]	Three-drug IO + platinum/etoposide
ECOG 2 / heavy comorbidities / elderly	IO + carboplatin + etoposide (avoid cisplatin), strengthen BSC	EP alone
Nephrotoxicity, cisplatin intolerant	lobaplatin + etoposide [EL-PHASE3-CHINA PMID 30988825] ± IO	carboplatin + etoposide
High risk of severe myelosuppression	Consider trilaciclib myeloprotection pre-dosing [TRACES PMID 38224653]	Dose reduction

Clinical meaning of “long-tail survivor”: IMBRELLA-A 5y OS 12% (PMID 39306923) tells us — ES-SCLC IO + chemo benefit is not uniformly lifting everyone 2-3 months, but giving about 12% of “durable responders” a 5-year+ survival window. When communicating prognosis, clinicians should clearly distinguish the dual-layer structure of “median OS 13-15 months (majority) + 5-year OS 12% (long tail).”

NCCN 2026: IO + platinum/etoposide = Category 1 preferred (atezolizumab / durvalumab globally; serplulimab / adebrelimab / tislelizumab / toripalimab in China based on CSCO 2025).

3.3 PCI Decision: Is PCI Still Needed in the IO Era?

2026 mainstream:

LS-SCLC cCRT + durvalumab consolidation CR patients: PCI 25 Gy remains SoC (PCI99-01 PMID 19386548 dose-locked); some centers switch to brain MRI q3-6 month surveillance as a PCI substitute (lacks head-to-head RCT)
ES-SCLC chemo + IO responders: Slotman 2007 (PMID 17699816) PCI 25 Gy remains standard evidence → but in the IO era (IMpower133 / CASPIAN both protocol-permitted PCI by investigator choice), actual usage has declined; brain MRI surveillance is the European alternative in some centers
HA-PCI (hippocampal-avoidance): RTOG-0212 PMID 33545387 did not show clear cognitive protection advantage, inconsistent with earlier small-scale data; NCCN retains as optional but not strongly recommended
Thoracic RT (TRT): CREST PMID 25230595 2-year OS 13% vs 3% significant + 1-year not significant — whether to add TRT in the IO era is in guideline “optional” status; TREASURE PMID 36153496 “IO + TRT” terminated due to toxicity suggests risk

Key controversy: is PCI still needed in the IO era? — this is the most divisive clinical question in SCLC 2026. No IO vs PCI head-to-head RCT; some European centers have already substituted MRI for PCI; Asian / North American majority still retain PCI. MAVERICK / PRIMALung phase III RCTs are enrolling but no readout as of 2026-04.

3.4 ES-SCLC 2L+: tarlatamab preferred + topotecan alternative + IO monotherapy not used

2026 mainstream:

Subgroup	First choice	Alternative
DLL3+ SCLC post-1L IO + chemo progression	tarlatamab 10 mg IV q2w [DeLLphi-301 PMID 37861218]	IV or oral topotecan
DLL3 not tested / not enriched	Oral topotecan [OBRIEN-TOPOTECAN-2006 PMID 17135646 vs BSC]	IV topotecan / lurbinectedin (FDA 2020 accelerated)
Prior good IO response + tarlatamab CRS intolerant	Rechallenge IO + chemo (if interval > 6 months)	Clinical trial
MSI-H / dMMR / TMB-H rare SCLC subgroup	pembrolizumab tumor-agnostic	nivolumab tumor-agnostic
3L+ standard exhausted	Clinical trial > regorafenib / ADC / CAR-T exploration	BSC

Not recommended in 2026:

nivolumab or pembrolizumab monotherapy in unselected SCLC 2L+ — CheckMate-032 (PMID 27269741) and KEYNOTE-028/158 (PMID 31870883) SCLC accelerated approvals were withdrawn by FDA 2020-12 / 2021-03 respectively. Only tumor-agnostic MSI-H / TMB-H subgroups retain IO monotherapy use.
CAV three-drug — single-agent topotecan is non-inferior (PMID 10080612) + single-agent more convenient + lower toxicity.

3.5 Maintenance / Combination Exploration: Four Directions Flourishing

2026 mainstream: ES-SCLC 1L IO + chemo × 4-6 cycles → IO maintenance until progression. On this foundation, four “IO maintenance intensification” directions are being explored:

Direction	Representative trial	2026 clinical status
tarlatamab maintenance (DLL3 BiTE + IO)	DeLLphi-303 [PMID 40934933] + phase III NCT06211036	Phase II 25.3-month mOS signal strong; phase III ongoing
anti-angiogenic + IO maintenance	DURABLE [PMID 37947242] durvalumab + anlotinib maintenance vs durvalumab	Protocol-only, awaiting primary readout; conference-reported PFS signal
Thoracic RT (TRT) + IO maintenance	TREASURE [PMID 36153496] (terminated due to toxicity)	TRT + IO maintenance approach failed; CREST-era TRT retained as standalone
Low-dose RT (LDRT) + IO + chemo concurrent	MATCH-TRIAL-SCLC [PMID 40609842]	Phase II ORR 87.5% signal strong, awaiting phase III validation

Clinical implication: these four directions represent “how much more benefit can be squeezed from ES-SCLC 1L maintenance” — DeLLphi-303 is most likely to rewrite 1L maintenance standard in 2026-2028 (phase III NCT06211036); MATCH LDRT + IO may reopen thoracic RT’s IO-era value; anti-angiogenic maintenance may be replaced by ETER701’s four-drug 1L regimen, eliminating the need for sequential “maintenance + anti-angio.”

3.6 Elderly / Poor PS SCLC + Transformed SCLC Subgroups

Elderly (≥75 years) / PS 2 ES-SCLC: IMpower133 / CASPIAN / ASTRUM-005 and other IO + chemo phase IIIs predominantly enrolled PS 0-1 (PS 2 <10%). Clinical decisions:

PS 2 but chemo-tolerant: dose-reduced IO + carboplatin (avoid cisplatin) + etoposide + trilaciclib myeloprotection (TRACES PMID 38224653)
PS 3-4 / multi-organ failure: BSC + palliative RT (symptomatic brain metastases / bone metastases)
85+ ES-SCLC: single-agent etoposide or single-agent IO (no dedicated RCT)

Transformed SCLC (EGFR TKI-resistant NSCLC transformed to SCLC): rare subgroup (about 3-10% of EGFR-mutated NSCLC post-osimertinib transforms to SCLC). No prospective RCT; clinical experience is to use SCLC-like chemo (EP/EC) + consider continuing osimertinib (to protect residual NSCLC clones). DeLLphi-301 and other tarlatamab trials typically exclude transformed SCLC — this subgroup has limited 2L+ treatment options, prioritize clinical trial enrollment.

4. Research Gaps: Top Ten Unresolved Clinical Questions

This report identifies the following gaps, all definable specific questions (not platitudes of “more research needed”):

“Within-group differences” across IMpower133 / CASPIAN / Chinese PD-1 series remain unresolved: HR 0.70-0.80 narrow-band convergence = class effect, but IMBRELLA-A 5y OS 12% means 88% of patients still progress rapidly — who is the long-tail responder? Lacks pre-specified PD-L1 / TMB / ASCL1 / dMMR / IFN-γ signature prospective validation.
PCI in the IO era vs MRI surveillance head-to-head missing: PCI standards established by Slotman 2007 and PCI99-01 have not been updated for the IO era; MAVERICK / PRIMALung phase III ongoing but no readout as of 2026-04 — East-West practice divergence (European MRI substitution / Asian-North American PCI retention) lacks evidence-based resolution.
LS-SCLC cCRT sequencing (concurrent vs sequential) contemporary data missing: TURRISI 1999 + CONVERT 2017 + CALGB 30610 2023 are all concurrent RT; sequential chemo + RT only as PS 2 alternative, no IO-era (post-ADRIATIC) concurrent vs sequential head-to-head data.
DLL3 biomarker cutoff not standardized: DeLLphi-301 enrolled DLL3 IHC ≥50% as marker, but is tarlatamab response cORR 40% limited to high expressors? Does any DLL3 expression also have activity? DLL3 IHC assay inter-laboratory variability + cutoff choice = key gap for future SCLC basket trials.
Transformed SCLC (EGFR TKI-resistant transformation) 1L/2L regimens lack prospective data: about 3-10% of NSCLC post-osimertinib transforms to SCLC; clinical decisions are entirely empirical. DeLLphi-301 and other tarlatamab trials exclude this subgroup; transformed SCLC-specific prospective cohort missing.
Clinical actionability of SCLC molecular subtypes (ASCL1 / NEUROD1 / POU2F3 / YAP1): since 2018 Rudin et al defined 4 molecular subtypes; POU2F3 high expression may correlate with lurbinectedin response, YAP1 with IO primary resistance — but no prospective stratified trial readout as of 2026-04, subtyping not routinely applied clinically.
Elderly / PS 2 ES-SCLC IO data sparse: IMpower133 / CASPIAN dominated by PS 0-1, PS 2 subgroup <10%; dedicated elderly / PS 2 SCLC IO RCT missing — clinical decisions based on post-hoc subgroup analyses rather than prespecified.
SCLC CNS progression local (SRS / WBRT) vs systemic (tarlatamab CNS activity) decision not standardized: tarlatamab CNS penetration data limited; IO + chemo CNS ORR not separately reported. Optimal sequencing of SRS + systemic therapy lacks RCT.
Post-2L+ 3L+ options (post-tarlatamab resistance): tarlatamab 2L response 6.9-month mDoR post-resistance has no standard; lacks tarlatamab resistance molecular mechanism characterization + 3L+ ADC / CAR-T / rechallenge chemo data.
Chinese PD-1 class effect internal differences (ASTRUM-005 HR 0.63 vs EXTENTORCH HR 0.80): HR spans 0.63-0.80 (18 percentage points) — is this a true difference or cross-trial population / control / follow-up duration difference? Lacks Chinese PD-(L)1 head-to-head RCT.

5. 2024-2026 Latest Developments

5.1 FDA / NMPA New Approvals and Guideline Expansions

2024-05-16 FDA accelerated approval: tarlatamab (Imdelltra) DLL3 × CD3 BiTE for SCLC 2L+ post-platinum chemo progression / DeLLphi-301 [PMID 37861218] — first non-chemotherapy non-IO new mechanism in SCLC in half a century
2024-08-05 FDA approval: durvalumab (Imfinzi) consolidation for LS-SCLC post-cCRT non-progressors / ADRIATIC [PMID 39268857] — first OS-positive phase III in LS-SCLC in 30 years changing SoC
2022-03 NMPA approval + 2024 global follow-up: adebrelimab (SHR-1316) + EC for ES-SCLC 1L / CAPSTONE-1 [PMID 35576956]
2022-10 NMPA approval: serplulimab (HLX10) + EC for ES-SCLC 1L / ASTRUM-005 [PMID 36166026]
2024 NMPA expanded approval: tislelizumab / toripalimab + EP/EC for ES-SCLC 1L / RATIONALE-312 [PMID 38460751] + EXTENTORCH [PMID 39541202]
2024-01 NMPA approval: benmelstobart + anlotinib + EC four-drug regimen for ES-SCLC 1L / ETER701 [PMID 38992123]
2021-02 FDA approval + 2024 China follow-up: trilaciclib (Cosela) myeloprotection for ES-SCLC chemotherapy / TRACES [PMID 38224653]

2020-12 / 2021-03 FDA withdrawals: nivolumab (CheckMate-032 PMID 27269741) and pembrolizumab (KEYNOTE-028/158 PMID 31870883) SCLC 3L monotherapy indications withdrawn due to confirmatory phase III failures — SCLC IO monotherapy 2L+ no longer recommended.

5.2 Key Conference Readouts (2024-2025, Down-Weighted Labeling)

The following entries serve only as candidate pool pending formal peer review and do not enter the main database. Items with PMIDs have been promoted.

ADRIATIC OS update (ASCO 2024 LBA5 → 2024-09 NEJM [PMID 39268857]): LS-SCLC cCRT + durvalumab consolidation mOS 55.9 vs 33.4 months — promoted to main database
DeLLphi-301 long-term follow-up (WCLC 2024 / ESMO 2024 oral): tarlatamab 10 mg long-term follow-up ORR + DoR maintained stable; does not change NEJM primary PMID 37861218 data
DeLLphi-302 (tarlatamab 2L+ placebo-controlled phase III): expected 2026 H2 primary readout, NCT05740566 enrollment complete — will provide first phase III head-to-head evidence for tarlatamab vs topotecan / lurbinectedin
ETER701 updated OS (ASCO 2024 / ESMO 2024): benmelstobart + anlotinib + EC four-drug regimen ES-SCLC 1L mOS 19.3 months — promoted to main database
DURABLE OS readout (expected 2025): durvalumab + anlotinib maintenance primary results still pending peer review; PMID 37947242 is protocol paper

5.3 Ongoing Phase III (Selected 2025-2028 Readouts)

DeLLphi-304 (NCT06211036) tarlatamab + atezolizumab/durvalumab 1L maintenance vs atezolizumab/durvalumab maintenance — expected 2026-2028 readout, the key trial to rewrite ES-SCLC 1L maintenance standard
DeLLphi-302 (NCT05740566) tarlatamab vs investigator choice (topotecan / lurbinectedin / topotecan + cyclophosphamide) in SCLC 2L — confirms 2L phase III-level evidence
MAVERICK / PRIMALung ES-SCLC post-chemo + IO response PCI vs MRI surveillance — head-to-head RCT, 2027-2028 readout
IMforte (NCT05091567) ES-SCLC 1L post-chemoimmunotherapy atezolizumab ± lurbinectedin maintenance — expected 2026 readout
Multiple DLL3 ADCs / CAR-T / other BiTEs (MK-6070 / HPN328 / BI 764532) phase I/II ongoing in SCLC 2L+

6. Intersection Insights and Judgment

6.1 Longitudinal × Horizontal: The 2026 SCLC Landscape Is Shaped by Three Resonances

Stacking the longitudinal paradigm evolution on the horizontal current decision landscape, the 2026 SCLC treatment landscape is actually shaped by three resonance overlays:

Chemotherapy 20-year plateau (mOS 9-10 months) → IO + chemo class effect (mOS 12-15 months + 5y long tail 12%): the EP backbone barely moved from 1999 TURRISI to 2018 IMpower133, and all attempts to add a third drug failed. After IO entered 1L, HR converged in 0.63-0.80 class effect, but median OS only gained 2-5 months — the real structural change is the 5-year OS long tail (IMBRELLA-A 5y 12%, chemo-alone historical 3-4%). Clinical prognosis communication should distinguish the dual-layer structure of “median OS” vs “long tail.”
LS-SCLC ADRIATIC first upgrade in 30 years + ES-SCLC class effect saturation + DLL3 BiTE breakthrough as a three-way standoff: 2024 was the densest year in SCLC history — ADRIATIC around May raised LS-SCLC cCRT-post mOS from 33 months to 56 months (+23 months, large delta); tarlatamab approval in May opened a non-chemotherapy new mechanism for 2L+; meanwhile ES-SCLC 1L class effect has saturated (six Chinese PD-1s in parallel, HR 0.63-0.80 differences driven mainly by population/control/follow-up).
“Biological stratification” of IO in SCLC — monotherapy failure vs combination success: CheckMate-032 + KEYNOTE-028/158 IO monotherapy ORR 10-22% but confirmatory phase III failed → FDA withdrew; the same IO after + chemo OS-positive → globally approved. This says SCLC cold-tumor biology (low TMB / immune-desert / no stable neoantigens) sets a low ceiling for IO monotherapy, and chemotherapy debulking + IO checkpoint release + maintenance is the minimum recipe for IO efficacy in SCLC — IO alone does not work in SCLC.

These three resonances together explain a clinical phenomenon: the decision tree for a newly diagnosed SCLC patient in 2026 has 3 more decision layers than in 2018 (LS vs ES staging + whether post-cCRT durvalumab consolidation + 1L IO 6-choose-1 including Chinese PD-1 accessibility branch + 2L tarlatamab DLL3 biomarker stratification).

6.2 Clinical Decision Takeaways (for Junior-Mid Oncologists)

After LS-SCLC cCRT, you must evaluate durvalumab consolidation eligibility: ADRIATIC (PMID 39268857) mOS 55.9 vs 33.4 months is the largest LS-SCLC delta in 30 years. Missing ADRIATIC consolidation = leaving the patient in the cCRT era.
Do not use “concurrent IO + cCRT” in LS-SCLC: NRG LU005 (PMID 41529214) HR 1.03 refuted the PACIFIC-like concurrent path’s replicability in SCLC. cCRT first, then durvalumab sequential.
ES-SCLC 1L IO class effect 6-choose-1: atezolizumab / durvalumab / serplulimab / adebrelimab / tislelizumab / toripalimab HR 0.63-0.80 narrow band; which one to pick depends on accessibility + reimbursement + tolerance. Don’t agonize over “which IO is better” — there is no phase III-level answer.
ES-SCLC 1L long-tail 12% 5-year survival is a key communication point: IMBRELLA-A (PMID 39306923) tells us IO + chemo is not a uniform 2-3 month extension, but gives 12% of patients a 5-year+ long tail. Clinical communication should clearly articulate the dual-layer “median + long tail” prognosis.
2L+ DLL3 testing + tarlatamab preferred: DeLLphi-301 (PMID 37861218) + FDA 2024-05 accelerated approval = first non-chemotherapy new mechanism in SCLC in half a century. DLL3 IHC testing + step-up dosing + CRS management form the three-part foundation of 2026 SCLC 2L basics.
IO monotherapy not recommended in SCLC 2L+: CheckMate-032 + KEYNOTE-028/158 accelerated approvals were withdrawn by FDA 2020-12 / 2021-03 respectively. Only tumor-agnostic MSI-H / TMB-H rare subgroups retained.
Tradeoff between ETER701 four-drug vs three-drug vs two-drug IO + EC: four-drug mOS 19.3 months is historical peak but G3+ TRAE 93% approaches universal; selection requires assessing performance status + comorbidities + tolerance expectations. Don’t default to “highest number = best.”
Attitude toward PCI in the IO era: post-LS-SCLC CR PCI 25 Gy remains standard (PCI99-01); post-ES-SCLC IO response PCI’s status has declined, brain MRI surveillance has become a European alternative — before head-to-head RCTs, PCI vs MRI is a matter of “center preference,” not “right or wrong.”
Transformed SCLC — prioritize clinical trials: EGFR TKI-resistant NSCLC transformed SCLC subgroup is typically excluded by DeLLphi-301 and other trials; standard EP/EC chemo predominates + consider continuing osimertinib to protect residual NSCLC clones.
Seven drug classes essential for SCLC in 2026: durvalumab (LS consolidation + ES 1L) / atezolizumab (ES 1L) / serplulimab + adebrelimab + tislelizumab + toripalimab (Chinese ES 1L 4-choose-1) / benmelstobart + anlotinib (ETER701 four-drug core) / tarlatamab (2L+ DLL3 BiTE) / topotecan (2L non-BiTE backstop) / trilaciclib (myeloprotection) — before 2018 SCLC had only EP + topotecan as two drugs; 2026 already has a 7+ class decision map across 5 pathways.

7. Information Sources

The 30 trials’ metadata in this report were independently cross-verified via PubMed and ClinicalTrials.gov. Each [PMID xxxxxxxx] in the text can be verified directly on PubMed.

Published trials: 28, covering 1999-2026 (PMID verifiable)
Protocol / design papers (primary results pending): 2 (DURABLE PMID 37947242 / TREASURE PMID 36153496 — the latter terminated due to toxicity)
NCCN guideline citations: 30/30 directly hit NCCN Small Cell Lung Cancer V1.2026 reference section or extended evidence base
2020-2025 FDA / NMPA new approvals: 10+ (durvalumab LS consolidation / atezolizumab 1L / serplulimab / adebrelimab / tislelizumab / toripalimab / benmelstobart + anlotinib / tarlatamab / trilaciclib)
2020-2021 FDA withdrawals: 2 (nivolumab SCLC 3L / pembrolizumab SCLC 3L — confirmatory phase III failed)
2024-2026 key conference readouts: 3 (DeLLphi-301 long-term / DeLLphi-302 phase III expected 2026 / ETER701 updated OS)
Research gaps: 10

7.1 Report Body Citation Index (Sorted by PMID Ascending)

The table below lists PMIDs bracket-cited in the body, each clickable on PubMed for verification.

PMID	Trial / Paper	Year	Journal	Body location §x.x
9920950	INT-0096 (TURRISI 1999)	1999	N Engl J Med	§2.1 / §3.1
10080612	TOPOTECAN-ORIGINAL-PHASE2	1999	J Clin Oncol	§2.2 / §3.4
15923572	NIELL-2002-INTERGROUP	2005	J Clin Oncol	§2.2
17135646	OBRIEN-TOPOTECAN-2006	2006	J Clin Oncol	§2.2 / §3.4
17699816	SLOTMAN-PCI-2007	2007	N Engl J Med	§2.3 / §3.3
19386548	PCI99-01	2009	Lancet Oncol	§2.3 / §3.1 / §3.3
25230595	CREST (SLOTMAN-2015)	2015	Lancet	§2.3 / §3.3
27269741	CHECKMATE-032	2016	Lancet Oncol	§2.5 / §3.4 / §5.1
28642008	CONVERT	2017	Lancet Oncol	§2.1 / §3.1
30280641	IMPOWER133	2018	N Engl J Med	§2.4 / §3.2
30988825	EL-PHASE3-CHINA	2019	Oncol Lett	§2.2 / §3.2
31590988	CASPIAN	2019	Lancet	§2.4 / §3.2
31870883	KEYNOTE-028-158	2020	J Thorac Oncol	§2.5 / §3.4 / §5.1
33545387	RTOG-0212-HIPPO (Belderbos 2021)	2021	J Thorac Oncol	§2.3 / §3.3
35576956	CAPSTONE-1	2022	Lancet Oncol	§2.4 / §3.2 / §5.1
36153496	TREASURE	2022	BMC Cancer	§2.5 / §3.5
36166026	ASTRUM-005	2022	JAMA	§2.4 / §3.2 / §5.1
36623230	CALGB-30610 / RTOG-0538	2023	J Clin Oncol	§2.1 / §3.1
37861218	DELLPHI-301	2023	N Engl J Med	§2.5 / §3.4 / §5.1 / §6.2
37947242	DURABLE (protocol)	2023	Clin Respir J	§2.5 / §3.5
38224653	TRACES	2024	Lung Cancer	§2.5 / §3.2 / §5.1
38460751	RATIONALE-312	2024	J Thorac Oncol	§2.4 / §3.2 / §5.1
38992123	ETER701	2024	Nat Med	§2.4 / §3.2 / §5.1
39146944	YU-2024-HYPERFRAC	2024	Lancet Respir Med	§2.1 / §3.1
39268857	ADRIATIC	2024	N Engl J Med	§2.1 / §3.1 / §5.1 / §6.2
39306923	IMBRELLA-A (IMpower133 5y)	2024	Lung Cancer	§2.4 / §3.2 / §6.2
39541202	EXTENTORCH	2025	JAMA Oncol	§2.4 / §3.2 / §5.1
40609842	MATCH-TRIAL-SCLC	2026	Int J Radiat Oncol Biol Phys	§2.5 / §3.5
40934933	DELLPHI-303	2025	Lancet Oncol	§2.5 / §3.5 / §5.3
41529214	NRG-LU005	2026	J Clin Oncol	§2.1 / §3.1

7.2 Verification Conventions

Each PMID is directly accessible via https://pubmed.ncbi.nlm.nih.gov/{PMID}/ for verification
Each NCT id is accessible via https://clinicaltrials.gov/study/{NCT_id}/
Conference abstracts (ASCO / ESMO / WCLC) are retrieved via the official meeting systems; all conference citations in this report are “down-weighted” — not peer-reviewed, final data subject to journal publication
DURABLE + TREASURE cited as protocol / design paper PMIDs; entries will be updated once primary efficacy manuscripts are published
If a PMID in this report is found to differ from PubMed on trial name / year / conclusion, corrections are welcome

Clinical Trial Timelines Here

Chinese: /trials/sclc/ English: /en/trials/sclc/

Each trial has an independent detail page including:

Complete intervention / comparator regimens
Primary endpoint values + 95% CI
Key findings + clinical significance
Clickable links to PMID / NCT originals

30 trials · 5 paradigms · 1999 to 2026 · synchronized with NCCN Small Cell Lung Cancer V1.2026.

Closing

SCLC has completed a unique evolutionary arc over the past 27 years — from 1999 TURRISI INT-0096 establishing LS-SCLC cCRT + BID 45 Gy, through the pre-2018 ES-SCLC 1L EP-backbone 20-year plateau with mOS stable at 9-10 months, to 2018 IMpower133 and 2019 CASPIAN opening the IO marginal-victory breakthrough with HR converging in 0.70-0.73 class effect.

2024 was the densest year in SCLC history: ADRIATIC upgraded LS-SCLC’s 30-year SoC to cCRT + durvalumab consolidation (mOS 55.9 vs 33.4 months, +23-month large delta); DeLLphi-301 tarlatamab received FDA accelerated approval, becoming the first non-chemotherapy non-IO new mechanism in SCLC in half a century; meanwhile five Chinese PD-1 / PD-L1 phase IIIs (ASTRUM-005 / CAPSTONE-1 / RATIONALE-312 / EXTENTORCH / ETER701) pushed ES-SCLC 1L into a “flourishing” era.

This “20-year plateau + IO marginal victory + DLL3 BiTE breakthrough” three-stage pattern is entirely different from NSCLC’s “5 paradigm shifts + 10 drivers all entering 1L + IO rewriting the backbone.” The driving force is SCLC’s unique biology — no unified driver mutation + neuroendocrine differentiation + low TMB + cold tumor + rapid chemoresistance + MYC/ASCL1/NEUROD1/POU2F3/YAP1 molecular subtype heterogeneity. SCLC’s paradigm breakthrough is not “finding a driver gene” but “finding a targetable cell-surface molecule (DLL3) + new mechanism (BiTE).”

For a newly diagnosed SCLC patient in 2026, the core decision-tree branchpoints are “first stage (LS vs ES) → post-cCRT durvalumab consolidation yes/no → 1L IO 6-choose-1 including Chinese accessibility branch → 2L DLL3 biomarker testing + tarlatamab preferred → PCI vs MRI per center preference.”

The value of this report lies not in “enumerating all trials” (PubMed can do that), but in compressing 27 years of evolution + current decisions + unresolved gaps into the cognitive bandwidth of a single reading. Next time you face a newly diagnosed SCLC patient, every branchpoint in the decision tree has this map to check, trace, and interrogate.

Clinician × AI = Research Superpower + Clinical Decision Amplifier

—— Dual Brain Lab · 2026-04-21

DLL3 on Dual Brain Lab